CONCLUSION:
Incidence of new onset atrial fibrillation evidenced to be less frequent
in patients with severe COVID-19 regardless of inflammatory burden,
however it proves to be a marker of poor prognosis. Despite
understanding the hypercoagulable milieu of the disease, the benefit of
anticoagulation for prevention of stroke during the course of severe
COVID-19 remains unclear. Furthers larger studies are warranted to
assess the incidence of stroke associated with NOAF in severe COVID-19
infection.
FUNDING: None